{
    "name": "Schedule I",
    "number": "14",
    "text": "(a)  The controlled substances listed in this section are included in schedule I.\n\t(b)  Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:\n\n\n\n\t(1)\tAcetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);\n\t(2)\tAcetylmethadol;\n\t(3)\tAllylprodine;\n\t(4)\tAlphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);\n\t(5)\tAlphameprodine;\n\t(6)\tAlphamethadol;\n\t(7)\tAlpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);\n\t(8)\tAlpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);\n\t(9)\tBenzethidine;\n\t(10)\tBetacetylmethadol;\n\t(11)\tBeta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide;\n\t(12)\tBeta-hydroxy-3-methylfentanyl (N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);\n\t(13)\tBetameprodine;\n\t(14)\tBetamethadol;\n\t(15)\tBetaprodine;\n\t(16)\tClonitazene;\n\t(17)\tDextromoramide;\n\t(18)\tDiampromide;\n\t(19)\tDiethylthiambutene;\n\t(20)\tDifenoxin;\n\t(21)\tDimenoxadol;\n\t(22)\tDimepheptanol;\n\t(23)\tDimethylthiambutene;\n\t(24)\tDioxaphetyl butyrate;\n\t(25)\tDipipanone;\n\t(26)\tEthylmethylthiambutene;\n\t(27)\tEtonitazene;\n\t(28)\tEtoxeridine;\n\t(29)\tFurethidine;\n\t(30)\tHydroxypethidine;\n\t(31)\tKetobemidone;\n\t(32)\tLevomoramide;\n\t(33)\tLevophenacylmorphan;\n\t(34)\t3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);\n\t(35)\t3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);\n\t(36)\tMorpheridine;\n\t(37)\tMPPP (1-methyl-4-phenyl-4-propionoxypiperidine);\n\t(38)\tNoracymethadol;\n\t(39)\tNorlevorphanol;\n\t(40)\tNormethadone;\n\t(41)\tNorpipanone;\n\t(42)\tPara-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide;\n\t(43)\tPEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;\n\t(44)\tPhenadoxone;\n\t(45)\tPhenampromide;\n\t(46)\tPhenomorphan;\n\t(47)\tPhenoperidine;\n\t(48)\tPiritramide;\n\t(49)\tProheptazine;\n\t(50)\tProperidine;\n\t(51)\tPropiram;\n\t(52)\tRacemoramide;\n\t(53)\tThiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);\n\t(54)\tTilidine;\n\t(55)\tTrimeperidine;\n\t(56)\tN-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers; and\n\t(57)\tN-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers.\n\n\n\n\t(c)  Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:\n\n\n\n\t(1)\tAcetorphine;\n\t(2)\tAcetyldihydrocodeine;\n\t(3)\tBenzylmorphine;\n\t(4)\tCodeine methylbromide;\n\t(5)\tCodeine-N-Oxide;\n\t(6)\tCyprenorphine;\n\t(7)\tDesomorphine;\n\t(8)\tDihydromorphine;\n\t(9)\tDrotebanol;\n\t(10)\tEtorphine;\n\t(11)\tHeroin;\n\t(12)\tHydromorphinol;\n\t(13)\tMethyldesorphine;\n\t(14)\tMethyldihydromorphine;\n\t(15)\tMorphine methylbromide;\n\t(16)\tMorphine methylsulfonate;\n\t(17)\tMorphine-N-Oxide;\n\t(18)\tMyrophine;\n\t(19)\tNicocodeine;\n\t(20)\tNicomorphine;\n\t(21)\tNormorphine;\n\t(22)\tPhoclodine;\n\t(23)\tThebacon.\n\n\n\n\t(d)  Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:\n\n\n\n\t(1)\tAlpha-ethyltryptamine (AET);\n\t(2)\t2,5-dimethoxy-4-ethylamphetamine (DOET);\n\t(3)\t2,5-dimethoxyamphetamine (2,5-DMA);\n\t(4)\t3,4-methylenedioxy amphetamine;\n\t(5)\t3,4-methylenedioxymethamphetamine (MDMA);\n\t(6)\tN-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);\n\t(7)\t3,4-methylenedioxy-N-ethylamphetamine (MDE);\n\t(8)\t5-methoxy-3,4-methylenedioxy-amphetamine;\n\t(9)\t4-bromo-2,5-dimethoxy-amphetamine(4-bromo-2,5-DMA);\n\t(10)\t4-Bromo-2,5-dimethoxyphenethylamine (Nexus);\n\t(11)\t3,4,5-trimethoxy amphetamine;\n\t(12)\tBufotenine;\n\t(13)\t4-methoxyamphetamine (PMA);\n\t(14)\tDiethyltryptamine;\n\t(15)\tDimethyltryptamine;\n\t(16)\t4-methyl-2,5-dimethoxy-amphetamine;\n\t(17)\tGamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);\n\t(18)\tIbogaine;\n\t(19)\tLysergic acid diethylamide;\n\t(20)\tMarijuana;\n\t(21)\tParahexyl;\n\t(22)\tMescaline;\n\t(23)\tPeyote;\n\t(24)\tN-ethyl-3-piperidyl benzilate;\n\t(25)\tN-methyl-3-piperidyl benzilate;\n\t(26)\tPsilocybin;\n\t(27)\tPsilocyn;\n\t(28)\t1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);\n\t(29)\tTetrahydrocannabinols;\n\t(30)\tEthylamine analog of phencyclidine (PCE);\n\t(31)\tPyrrolidine analog of phencyclidine (PCPy, PHP);\n\t(32)\tThiophene analog of phencyclidine (TPCP; TCP);\n\t(33)\tGamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)-furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion; \n\t(34)\t1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;\n\t(35)\t2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers; \n\t(36)\tN-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;\n\t(37)\t1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;\n\t(38)\tAlpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers; and\n\t(39)\t5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers.\n\n\n\n\t(e)  Unless specifically excepted, the schedule shall include any material, compound, mixture, or preparation which contains any quantity of the substance:\n\n\n\n\t(1)\tMecloqualone;\n\t(2)\tMethaqualone.\n\n\n\n\t(f)  Stimulants.  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:\n\n\n\n\t(1)\tAminorex;\n\t(2)\tCathinone;\n\t(3)\tFenethylline;\n\t(4)\tMethcathinone;\n\t(5)\tN-ethylamphetamine;\n\t(6)\t4-methylaminorex;\n\t(7)\tN,N-dimethylamphetamine. [L 1972, c 10, pt of \u00a71; am L 1974, c 217, \u00a71; am L 1977, c 116, \u00a71; am L 1978, c 68, \u00a72; am L 1979, c 194, \u00a71; am L 1980, c 140, \u00a71 and c 232, \u00a716; am L 1984, c 166, \u00a71; am L 1985, c 150, \u00a71; am L 1986, c 214, \u00a7\u00a72, 3; am L 1988, c 59, \u00a71; am L 1990, c 138, \u00a73; am L 1993, c 8, \u00a71; am L 1995, c 122, \u00a71; am L 1997, c 356, \u00a71; am L 1999, c 252, \u00a72; am L 2000, c 98, \u00a71; am L 2001, c 203, \u00a72; am L 2003, c 151, \u00a7\u00a71, 2]\n\n\n\n\nCase Notes\n\n  Proscription of distribution of lysergic acid \"diethylamine\" under this section (1974) cannot be extended by analogy under \u00a7701-104 to distribution of lysergic acid diethylamide.  61 H. 74, 595 P.2d 288."
}